Lancet Neurol:抗栓治疗者进行腰穿的建议

2018-04-07 杨中华 脑血管病及重症文献导读

2018年3月来自荷兰的Joost M Costerus等在Lancet Neurology上发表了题为《神经系统疾病腰椎穿刺的技术进展和适应症的变化》的文章,现将文中表1<腰穿前停用抗栓药物时间间隔的意见>翻译如下:

2018年3月来自荷兰的Joost M Costerus等在Lancet Neurology上发表了题为《神经系统疾病腰椎穿刺的技术进展和适应症的变化》的文章,现将文中表1<腰穿前停用抗栓药物时间间隔的意见>翻译如下:



译者注:

这些推荐意见来自于欧洲麻醉学会的推荐意见,目的在于降低出血的并发症。但是并没有循证医学证据,这些意见主要是基于药物动力性而制定的。不一定适用于所有患者,比如怀疑化脑并且长期服用氯吡格雷的患者,等7天再去腰穿确诊是不可能的。

原始出处:
Joost M Costerus, et al. Technological advances and changing indications for lumbar puncture in neurological disorders. Lancet Neurol. 2018 Mar;17(3):268-278. doi: 10.1016/S1474-4422(18)30033-4.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2000381, encodeId=7bd5200038161, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Nov 27 21:15:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654246, encodeId=a915165424633, content=<a href='/topic/show?id=14ab854818f' target=_blank style='color:#2F92EE;'>#腰穿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85481, encryptionId=14ab854818f, topicName=腰穿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a424484143, createdName=ysjykql, createdTime=Tue Jul 31 12:15:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829574, encodeId=915e18295e474, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 13 01:15:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306180, encodeId=1e4a306180b0, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Apr 16 05:23:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303566, encodeId=32d7303566c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 07 13:08:24 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303554, encodeId=64b4303554c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Sat Apr 07 11:50:28 CST 2018, time=2018-04-07, status=1, ipAttribution=)]
    2018-11-27 yinhl1978
  2. [GetPortalCommentsPageByObjectIdResponse(id=2000381, encodeId=7bd5200038161, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Nov 27 21:15:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654246, encodeId=a915165424633, content=<a href='/topic/show?id=14ab854818f' target=_blank style='color:#2F92EE;'>#腰穿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85481, encryptionId=14ab854818f, topicName=腰穿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a424484143, createdName=ysjykql, createdTime=Tue Jul 31 12:15:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829574, encodeId=915e18295e474, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 13 01:15:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306180, encodeId=1e4a306180b0, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Apr 16 05:23:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303566, encodeId=32d7303566c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 07 13:08:24 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303554, encodeId=64b4303554c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Sat Apr 07 11:50:28 CST 2018, time=2018-04-07, status=1, ipAttribution=)]
    2018-07-31 ysjykql
  3. [GetPortalCommentsPageByObjectIdResponse(id=2000381, encodeId=7bd5200038161, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Nov 27 21:15:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654246, encodeId=a915165424633, content=<a href='/topic/show?id=14ab854818f' target=_blank style='color:#2F92EE;'>#腰穿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85481, encryptionId=14ab854818f, topicName=腰穿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a424484143, createdName=ysjykql, createdTime=Tue Jul 31 12:15:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829574, encodeId=915e18295e474, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 13 01:15:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306180, encodeId=1e4a306180b0, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Apr 16 05:23:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303566, encodeId=32d7303566c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 07 13:08:24 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303554, encodeId=64b4303554c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Sat Apr 07 11:50:28 CST 2018, time=2018-04-07, status=1, ipAttribution=)]
    2018-11-13 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=2000381, encodeId=7bd5200038161, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Nov 27 21:15:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654246, encodeId=a915165424633, content=<a href='/topic/show?id=14ab854818f' target=_blank style='color:#2F92EE;'>#腰穿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85481, encryptionId=14ab854818f, topicName=腰穿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a424484143, createdName=ysjykql, createdTime=Tue Jul 31 12:15:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829574, encodeId=915e18295e474, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 13 01:15:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306180, encodeId=1e4a306180b0, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Apr 16 05:23:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303566, encodeId=32d7303566c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 07 13:08:24 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303554, encodeId=64b4303554c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Sat Apr 07 11:50:28 CST 2018, time=2018-04-07, status=1, ipAttribution=)]
    2018-04-16 青山颖钰

    谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2000381, encodeId=7bd5200038161, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Nov 27 21:15:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654246, encodeId=a915165424633, content=<a href='/topic/show?id=14ab854818f' target=_blank style='color:#2F92EE;'>#腰穿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85481, encryptionId=14ab854818f, topicName=腰穿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a424484143, createdName=ysjykql, createdTime=Tue Jul 31 12:15:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829574, encodeId=915e18295e474, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 13 01:15:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306180, encodeId=1e4a306180b0, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Apr 16 05:23:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303566, encodeId=32d7303566c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 07 13:08:24 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303554, encodeId=64b4303554c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Sat Apr 07 11:50:28 CST 2018, time=2018-04-07, status=1, ipAttribution=)]
    2018-04-07 121832a9m88暂无昵称

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2000381, encodeId=7bd5200038161, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Tue Nov 27 21:15:00 CST 2018, time=2018-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654246, encodeId=a915165424633, content=<a href='/topic/show?id=14ab854818f' target=_blank style='color:#2F92EE;'>#腰穿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85481, encryptionId=14ab854818f, topicName=腰穿)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3a424484143, createdName=ysjykql, createdTime=Tue Jul 31 12:15:00 CST 2018, time=2018-07-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829574, encodeId=915e18295e474, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Nov 13 01:15:00 CST 2018, time=2018-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=306180, encodeId=1e4a306180b0, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/18/9fba4e8a3782366829a5645367fdb658.jpg, createdBy=b5732293938, createdName=青山颖钰, createdTime=Mon Apr 16 05:23:59 CST 2018, time=2018-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303566, encodeId=32d7303566c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Sat Apr 07 13:08:24 CST 2018, time=2018-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=303554, encodeId=64b4303554c6, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJpBl6xwMmnsKibwxcAIltOH3nnCEQbNE6TDbYtCKe8hYI0oJrbduNqnJraM1PyyjPKU1suAzicYPaA/132, createdBy=eeaf2031798, createdName=海之蓝, createdTime=Sat Apr 07 11:50:28 CST 2018, time=2018-04-07, status=1, ipAttribution=)]
    2018-04-07 海之蓝

    学习

    0

相关资讯

超全总结,冠心病抗栓遭遇消化道出血怎么治?

冠心病患者抗栓治疗中如何评估消化道出血风险?在冠心病抗栓治疗中出现消化道出血患者应该如何调整抗栓策略?

四表在手,天下我有!教你轻松搞定外科会诊

随着人口老龄化进程加速,住院患者岁数越来越大,高龄老人通常会合并多种疾病,心脏病是肯定少不了的,当外科患者请心内科会诊时,我们总是一脸茫然,此类患者该如何抗栓呢?

GW-ICC 2016:韩雅玲教授谈冠心病抗栓诊治中国临床循环及指南共识

导语:2016年,长城会首次与世界心力衰竭大会2016(WHFC 2016)和国际心血管药物治疗学会年会(ISCP)联合召开。会议上,来自沈阳军区总医院的韩雅玲教授分享了《冠心病抗栓诊治中国临床循环及指南共识》。韩教授现任沈阳军区总医院副院长兼全军心血管病研究所所长、心血管内科主任,心血管内科教授,主任医师,第三、四军医大学、大连医科大学等兼职教授,博士生导师,著名的心血管病专家,国家药品评审专家

马长生:房颤抗栓治疗该告别阿司匹林时代

首都医科大学附属北京安贞医院   郭雪原 马长生房颤是临床上最常见的心律失常之一,是导致卒中和外周动脉栓塞重要的独立危险因素。大量随机对照研究、队列研究及注册研究数据均显示,口服抗凝药(华法林)在预防房颤栓塞中作用显著优于阿司匹林。且越来越多的证据表明,与口服抗凝药物相比,阿司匹林预防房颤卒中的作用有限。预防栓塞华法林远优于阿司匹林以 往荟萃分析表明,与安慰剂或对照组相比,华法林卒

Eur Heart J:伴肾衰竭的房颤患者可安全应用抗栓治疗

瑞典一项研究表明,大部分伴肾衰竭的房颤患者可从房颤推荐血栓预防治疗中获益,并且无需设置更高或更低的治疗阈值。增加肾衰竭附加分的CHADS2和CHA2DS2-VASc分数并未提高预测价值。论文于4月9日在线发表于《欧洲心脏杂志》(Eur Heart J)。 此项回顾性非随机研究共纳入307351例房颤患者,其中13435例既往被诊断为肾衰竭。依据抗凝策略不同,在伴有肾衰竭的房颤患者中对缺血性卒

房颤、>80岁患者和女性ACS患者该如何选择抗栓药物?

急性冠状动脉综合征患者抗栓药物的选择以及治疗策略始终是研究热点,随着研究不断深入以及研究人群的不断扩大,对于一些特殊患者的治疗方面有不少新的研究结果。中国医学科学院阜外医院袁晋青、王欢欢等就此在本刊针对以下三类人群相关最新研究进行了详细阐述和总结。 急性冠状动脉综合征合并心房颤动:或应双联抗血小板 临床上约1/3 的心房颤动合并冠心病,急性心肌梗死患者合并心房颤动或心